274 related articles for article (PubMed ID: 17110089)
1. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
Abu-Baker A; Rouleau GA
Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
[TBL] [Abstract][Full Text] [Related]
2. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy.
Fan X; Rouleau GA
Can J Neurol Sci; 2003 Feb; 30(1):8-14. PubMed ID: 12619777
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
[TBL] [Abstract][Full Text] [Related]
4. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy.
Bengoechea R; Tapia O; Casafont I; Berciano J; Lafarga M; Berciano MT
Neurobiol Dis; 2012 Apr; 46(1):118-29. PubMed ID: 22249111
[TBL] [Abstract][Full Text] [Related]
5. Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease.
Brais B
Cytogenet Genome Res; 2003; 100(1-4):252-60. PubMed ID: 14526187
[TBL] [Abstract][Full Text] [Related]
6. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy.
Harish P; Malerba A; Dickson G; Bachtarzi H
Hum Gene Ther; 2015 May; 26(5):286-92. PubMed ID: 25860803
[TBL] [Abstract][Full Text] [Related]
7. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
[TBL] [Abstract][Full Text] [Related]
8. Animal model of oculopharyngeal muscular dystrophy.
Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
[TBL] [Abstract][Full Text] [Related]
9. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
[TBL] [Abstract][Full Text] [Related]
10. PABPN1 gene therapy for oculopharyngeal muscular dystrophy.
Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G
Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972
[TBL] [Abstract][Full Text] [Related]
11. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
[TBL] [Abstract][Full Text] [Related]
12. Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1.
Malerba A; Klein P; Lu-Nguyen N; Cappellari O; Strings-Ufombah V; Harbaran S; Roelvink P; Suhy D; Trollet C; Dickson G
Hum Mol Genet; 2019 Oct; 28(19):3301-3308. PubMed ID: 31294444
[TBL] [Abstract][Full Text] [Related]
13. Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1.
García-Castañeda M; Vega AV; Rodríguez R; Montiel-Jaen MG; Cisneros B; Zarain-Herzberg A; Avila G
J Physiol; 2017 Jul; 595(13):4167-4187. PubMed ID: 28303574
[TBL] [Abstract][Full Text] [Related]
14. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients.
Gidaro T; Negroni E; Perié S; Mirabella M; Lainé J; Lacau St Guily J; Butler-Browne G; Mouly V; Trollet C
J Neuropathol Exp Neurol; 2013 Mar; 72(3):234-43. PubMed ID: 23399899
[TBL] [Abstract][Full Text] [Related]
15. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Rose C; Sarkar S; Rubinsztein DC
Sci Transl Med; 2010 Jun; 2(34):34ra40. PubMed ID: 20519718
[TBL] [Abstract][Full Text] [Related]
16. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.
Chartier A; Benoit B; Simonelig M
EMBO J; 2006 May; 25(10):2253-62. PubMed ID: 16642034
[TBL] [Abstract][Full Text] [Related]
17. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
Corbeil-Girard LP; Klein AF; Sasseville AM; Lavoie H; Dicaire MJ; Saint-Denis A; Pagé M; Duranceau A; Codère F; Bouchard JP; Karpati G; Rouleau GA; Massie B; Langelier Y; Brais B
Neurobiol Dis; 2005 Apr; 18(3):551-67. PubMed ID: 15755682
[TBL] [Abstract][Full Text] [Related]
18. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
[TBL] [Abstract][Full Text] [Related]
19. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.
Trollet C; Anvar SY; Venema A; Hargreaves IP; Foster K; Vignaud A; Ferry A; Negroni E; Hourde C; Baraibar MA; 't Hoen PA; Davies JE; Rubinsztein DC; Heales SJ; Mouly V; van der Maarel SM; Butler-Browne G; Raz V; Dickson G
Hum Mol Genet; 2010 Jun; 19(11):2191-207. PubMed ID: 20207626
[TBL] [Abstract][Full Text] [Related]
20. Oculopharyngeal muscular dystrophy: a polyalanine myopathy.
Brais B
Curr Neurol Neurosci Rep; 2009 Jan; 9(1):76-82. PubMed ID: 19080757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
